Klotho Neurosciences, Inc. (KLTO)
| Market Cap | 7.26M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -4.21M |
| Shares Out | 21.26M |
| EPS (ttm) | -0.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,150 |
| Open | 0.321 |
| Previous Close | 0.339 |
| Day's Range | 0.320 - 0.360 |
| 52-Week Range | 0.260 - 13.100 |
| Beta | -0.23 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 19, 2025 |
About KLTO
Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurodegenerative diseases, cancer, and other age-related pathologies. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing a... [Read more]
News
Klotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco
NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral sclerosis...
ANEW MEDICAL, INC. Secures Key Patent in Europe for Human Klotho Gene RNA Slice Variant and Protein
ANEW to explore therapeutics and specialty diagnostics utilizing the s-KL protein and will pursue other medical product development and commercial opportunities of interest Exclusive, worldwide intell...